Charles C. Wykoff, MD, PhD

Payer step therapy and formulary limits reshape anti‑VEGF care—often raising long‑term costs and risking outcomes without doctor–payer alignment.

Experts question prior authorization for anti-VEGF retina drugs, urging outcome-based reviews and payer-physician dialogue to cut waste and costs.

Open-access anti‑VEGF choices cut delays in AMD, DME and RVO care, urging payer-physician collaboration for sustainable costs and better vision.

How longer-lasting anti-VEGF therapies cut injections, visits, and vision loss risk—why payers may save overall by covering newer retinal drugs.

Rising anti‑VEGF drug prices, Medicare copays, and travel burdens reshape retinal disease care—see how affordability drives real‑world treatment choices.

Learn how treat-and-extend anti-VEGF dosing cuts injections in retinal disease and why real-world evidence should guide payer access.

How treat-and-extend anti-VEGF care lowers injection burden and reshapes payer access decisions, guided by real-world evidence.

How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with new-generation treatments.

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Explore how high-dose aflibercept and dual-pathway faricimab boost anti-VEGF durability, targeting VEGF-A and Ang-2 for better retinal outcomes.

Clinicians tailor treat-and-extend anti-VEGF care, using newer agents to control faster and stretch injections to 20 weeks, reducing burden.

Learn how next‑gen anti‑VEGF therapies rapidly control wet AMD, DME and vein occlusion, cutting injections and protecting vision.

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing cuts clinic burden, affects costs, and reveals key evidence gaps for AMD, DME, and RVO.

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of patient groups for the rare condition.

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, said.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy indicated for the treatment of macular telangiectasia type 2 (MacTel).